

1 **Delta variants of SARS-CoV-2 cause significantly increased** 2 **vaccine breakthrough COVID-19 cases in Houston, Texas**

3

4

5 Paul A. Christensen,^{*,†,‡} Randall J. Olsen,^{*,†,‡} S. Wesley Long,^{*,†,‡} Sishir Subedi,[†] James

6 J. Davis,^{§,¶} Parsa Hodjat,[†] Debbie R. Walley,[†] Jacob C. Kinskey,[†] Matthew Ojeda

7 Saavedra,[†] Layne Pruitt,[†] Kristina Reppond,[†] Madison N. Shyer,[†] Jessica Cambric,[†]

8 Ryan Gadd,[†] Rashi M. Thakur,[†] Akanksha Batajoo,[†] Regan Mangham,[†] Sindy Pena,[†]

9 Trina Trinh,[†] Prasanti Yerramilli,[†] Marcus Nguyen,^{§,¶} Robert Olson,^{§,¶} Richard Snehal,[†]

10 Jimmy Gollihar,^{†,#} James M. Musser,^{†,‡,**}

11

12 **Contributed equally;*

13 *†Laboratory of Human Molecular and Translational Human Infectious Diseases, Center*

14 *for Infectious Diseases, Houston Methodist Research Institute and Department of*

15 *Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas 77030;*

16 *‡Department of Pathology and Laboratory Medicine, Weill Cornell Medical College,*

17 *1300 York Avenue, New York City, New York 10065;*

18 *§Consortium for Advanced Science and Engineering, 22 University of Chicago, 5801*

19 *South Ellis Avenue, Chicago, Illinois, 60637;*

20 ¶ *Computing, Environment and Life Sciences, Argonne National Laboratory, 9700 South*

21 *Cass Avenue, Lemont, Illinois, 60439;*

22 *#DEVCOM Army Research Laboratory-South, Austin, Texas 78712*

23

24 ***Address correspondence to James M. Musser, M.D., Ph.D., Department of Pathology*

25 *and Genomic Medicine, Houston Methodist Research Institute, 6565 Fannin Street,*

26 *Suite B490, Houston, Texas 77030. Tel: 713.441.5890, E-mail:*

27 jmmusser@houstonmethodist.org

28

29 Running head: Delta variants and vaccine breakthrough

30

31 Disclosures: None.

32

33 Number of text pages: 15

34 Number of tables: 3

35 Number of figures: 4

36

37 Funding: This project was supported by the Houston Methodist Academic Institute

38 Infectious Diseases Fund; and supported in whole or in part with federal funds from the

39 National Institute of Allergy and Infectious Diseases, National Institutes of Health,

40 Department of Health and Human Services, under Contract No. 75N93019C00076

41 (J.J.D. and R.O.).

42 **Abstract**

43 Genetic variants of SARS-CoV-2 have repeatedly altered the course of the COVID-19
44 pandemic. Delta variants of concern are now the focus of intense international attention
45 because they are causing widespread COVID-19 disease globally and are associated
46 with vaccine breakthrough cases. We sequenced the genomes of 12,221 SARS-CoV-2
47 from samples acquired March 15, 2021 through August 26, 2021 in the Houston
48 Methodist hospital system. This sample represents 88% of all Methodist system COVID-
49 19 patients during the study period. Delta variants increased rapidly from late April
50 onward to cause 99.7% of all COVID-19 cases and spread throughout the Houston
51 metroplex. Compared to other variants, Delta caused a significantly higher rate of
52 vaccine breakthrough cases (23.4% compared to 6.2% for all other variants combined).
53 Importantly, significantly fewer fully vaccinated individuals required hospitalization.
54 Individuals with vaccine breakthrough cases caused by Delta had a low median PCR
55 cycle threshold (Ct) value (a proxy for high virus load). This value was closely similar to
56 the median Ct value for unvaccinated patients with COVID-19 caused by Delta variants,
57 suggesting that fully vaccinated individuals can transmit SARS-CoV-2 to others.
58 Patients infected with Alpha and Delta variants had several significant differences. Our
59 integrated analysis emphasizes that vaccines used in the United States are highly
60 effective in decreasing severe COVID-19 disease, hospitalizations, and deaths.

61

62

63

64 [Introduction]

65

66 Delta variants of concern (VOCs) of SARS-CoV-2 such as B.1.617.2, AY.3, and AY.4

67 are the focus of intense international concern because they are causing widespread

68 COVID-19 disease in the United States, Southeast Asia, Europe, and elsewhere

69 ([https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-](https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html)

70 [info.html](https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html), last accessed: August 18, 2021;

71 <https://www.gov.uk/government/collections/new-sars-cov-2-variant>, last accessed:

72 August 18, 2021)¹. For example, Delta has replaced the Alpha variant in the United

73 Kingdom, previously the cause of virtually all COVID-19 cases in that country

74 ([https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---13-july-2021)

75 [13-july-2021](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---13-july-2021), last accessed August 18, 2021;

76 <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditions>

77 [anddiseases/bulletins/coronaviruscovid19infectionsurveyspilot/9july2021](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditions), last accessed

78 August 18, 2021). Vaccine breakthrough cases caused by SARS-CoV-2 variants also

79 have become of considerable public health and biomedical concern worldwide²⁻⁶. To

80 study Delta spread and vaccine breakthrough cases in metropolitan Houston, we

81 sequenced the genomes of 12,221 SARS-CoV-2 from patient samples acquired March

82 15, 2021 through August 26, 2021 using an Illumina NovaSeq 6000 instrument and

83 methods described previously^{7, 8}. This period includes the time from initial identification

84 of Delta-related VOCs in late April in our large Houston Methodist healthcare system

85 until Delta VOCs caused the supermajority (99%) of all new cases. The sequenced

86 sample is 88% of the 13,839 total COVID-19 cases diagnosed in our health system
87 during the study period. We also compared characteristics of patients infected with
88 Alpha and Delta VOCs, an analysis that identified several significant differences
89 between patients infected with these two variants.

90

91

92 **Materials and Methods**

93

94 **Patient Specimens**

95

96 Specimens were obtained from registered patients at Houston Methodist hospitals,
97 associated facilities (e.g., urgent care centers), and institutions in the Houston
98 metropolitan region that use our laboratory services. The great majority of individuals
99 had signs or symptoms consistent with COVID-19 disease. For analyses focusing on
100 the Delta family variants, a comprehensive sample of genomes obtained from March 15,
101 2021 through August 26, 2021. This time frame was chosen because it represents the
102 period during which the downturn of our third wave was occurring, and soon after we
103 identified the first Delta variant case in our health care system. Subsequently, Delta
104 variants increased rapidly to become 99.7% of all cases. The study included 12,221
105 unique patients identified in this time frame for whom we had SARS-CoV-2 genome
106 sequences. For analyses comparing features of patients infected with the Delta variants

107 and Alpha VOC, a comprehensive sample of genomes obtained from January 1, 2021
108 through August 26, 2021. This time frame represents the period during which we
109 identified the first Alpha variant case in our health care system. This VOC increased
110 rapidly and peaked, and then decreased to cause less than 1% of all cases in the
111 region. This part of the study included 23,665 unique patients identified in the January
112 1, 2021 through August 26, 2021 period. The work was approved by the Houston
113 Methodist Research Institute Institutional Review Board (IRB1010-0199).

114

115 SARS-CoV-2 Molecular Diagnostic Testing

116

117 Specimens obtained from symptomatic patients with a suspicion for COVID-19 disease
118 were tested in the Molecular Diagnostics Laboratory at Houston Methodist Hospital
119 using assays granted Emergency Use Authorization (EUA) from the FDA
120 ([https://www.fda.gov/medical-devices/emergency-situations-medical-devices/faqs-
121 diagnostic-testing-sars-cov-2#offeringtests](https://www.fda.gov/medical-devices/emergency-situations-medical-devices/faqs-diagnostic-testing-sars-cov-2#offeringtests), last accessed June 7, 2021). Multiple
122 molecular testing platforms were used, including the COVID-19 test or RP2.1 test with
123 BioFire Film Array instruments, the Xpert Xpress SARS-CoV-2 test using Cepheid
124 GeneXpert Infinity or Cepheid GeneXpert Xpress IV instruments, the cobas SARS-CoV-
125 2 & Influenza A/B Assay using the Roche Liat system, the SARS-CoV-2 Assay using
126 the Hologic Panther instrument, the Aptima SARS-CoV-2 Assay using the Hologic
127 Panther Fusion system, the Cobas SARS-CoV-2 test using the Roche 6800 system,
128 and the SARS-CoV-2 assay using Abbott Alinity m instruments. Virtually all tests were

129 performed on material obtained from nasopharyngeal swabs immersed in universal
130 transport media (UTM); oropharyngeal or nasal swabs, bronchoalveolar lavage fluid, or
131 sputum treated with dithiothreitol (DTT) were sometimes used. Standardized specimen
132 collection methods were used (<https://vimeo.com/396996468/2228335d56>, last
133 [accessed June 7, 2021](#)).

134

135 SARS-CoV-2 Genome Sequencing

136

137 Libraries for whole SARS-CoV-2 genome sequencing were prepared according to
138 version 3 or version 4 ([https://community.artic.network/t/sars-cov-2-version-4-scheme-
139 release/312](https://community.artic.network/t/sars-cov-2-version-4-scheme-release/312), last accessed August 19, 2021) of the ARTIC nCoV-2019 sequencing
140 protocol. We used a semi-automated workflow described previously^{7, 8} that employed
141 BioMek i7 liquid handling workstations (Beckman Coulter Life Sciences) and MANTIS
142 automated liquid handlers (FORMULATRIX). Short sequence reads were generated
143 with a NovaSeq 6000 instrument (Illumina). For continuity of the epidemiologic analysis
144 in the study period, we included some genome sequences reported in a recent
145 publication.⁸

146

147 SARS-CoV-2 Genome Sequence Analysis and Identification of Variants

148

149 Viral genomes were assembled with the BV-BRC SARS-Cov2 assembly service
150 (<https://www.bv-brc.org/app/ComprehensiveSARS2Analysis>, last accessed June 7,

151 2021, requires registration). The One Codex SARS-CoV-2 variant calling and
152 consensus assembly pipeline was used to assemble all sequences
153 (<https://github.com/onecodex/sars-cov-2.git>, last accessed June 7, 2021) using default
154 parameters and a minimum read depth of 3. Briefly, the pipeline uses seqtk version 1.3-
155 r116 for sequence trimming (<https://github.com/lh3/seqtk.git>, last accessed June 7,
156 2021); minimap version 2.1 for aligning reads against reference genome Wuhan-Hu-1
157 (NC_045512.2); samtools version 1.11 for sequence and file manipulation; and iVar
158 version 1.2.2 for primer trimming and variant calling. Genetic lineages, VOCs, and
159 variants of interest (VOIs) were identified based on genome sequence data and
160 designated by Pangolin v. 3.1.11 with pangoLEARN module 2021-08-09 ([https://cov-](https://cov-lineages.org/resources/pangolin.html)
161 [lineages.org/resources/pangolin.html](https://cov-lineages.org/resources/pangolin.html), last accessed August 18, 2021).

162 There is a known problem with the ARTIC V3 primer set that results in lack of
163 detection or ambiguity of the G142D and D950N single nucleotide variants, even though
164 these amino acid changes (142D and 950N) are present in the overwhelming majority of
165 B.1.617.2 Delta variant isolates ([https://community.artic.network/t/sars-cov-2-version-4-](https://community.artic.network/t/sars-cov-2-version-4-scheme-release/312)
166 [scheme-release/312](https://community.artic.network/t/sars-cov-2-version-4-scheme-release/312), last accessed September 1, 2021, [https://outbreak.info/compare-](https://outbreak.info/compare-lineages?pango=B.1.617.2&gene=S&threshold=0.2)
167 [lineages?pango=B.1.617.2&gene=S&threshold=0.2](https://outbreak.info/compare-lineages?pango=B.1.617.2&gene=S&threshold=0.2), last accessed September 1, 2021).
168 After we transitioned to ARTIC V4, we observed that all Delta variant strain haplotypes
169 contained both 142D and 950N polymorphisms except for four isolates, two of which
170 lacked 142D and two which lacked 950N. Thus, for the Delta isolates presented here,
171 virtually all samples sequenced with ARTIC V3 are presumed to have G142D and
172 D950N.

173

174 Patient Metadata and Geospatial Analysis

175

176 Patient metadata (**Table 1, Table 2, Table 3**) were acquired from the electronic medical
177 record by standard informatics methods. Patient home address zip codes were used to
178 visualize the geospatial distribution of spread for each VOC and VOI. Figures were
179 generated with Tableau version 2020.3.4 ([Tableau Software, LLC, Seattle, WA](https://www.tableau.com/)). A
180 vaccination breakthrough case was defined as a PCR-positive sample from a patient
181 obtained greater than 14 days after full vaccination (i.e., both doses of the Pfizer or
182 Moderna mRNA vaccines) was completed. For some cases, manual chart review was
183 conducted to resolve discrepancies or ambiguities.

184

185

186 Results

187

188 Delta Epidemiologic Wave

189

190 The first Houston Methodist patient infected with a Delta family variant was identified in
191 mid-April, 2021, a time when the Alpha VOC was responsible for most COVID-19 cases
192 in metropolitan Houston, and the area was experiencing a steady downturn in total
193 number of new COVID-19 cases (**Figure 1**). Delta VOCs slowly increased in frequency,

194 but beginning in early July a sharp uptick of COVID-19 cases caused by these VOCs
195 occurred (**Figure 1, Figure 2**), with an estimated doubling time of approximately seven
196 days. By late August, the genome data showed that Delta VOCs accounted for 99.7% of
197 all new COVID-19 cases in our health system (**Figure 2**). This represents the fourth
198 wave of COVID-19 cases in metropolitan Houston (**Figure 1**).

199 During the study period 13,839 COVID-19 cases were diagnosed in our
200 healthcare system, and we sequenced 12,221 SARS-CoV-2 genomes, representing
201 88% of cases. We identified 8,297 patients (67.9% of the total sequenced) with Delta
202 VOCs (Table 1A). The majority (62%; 2,443 of 3,924) of the non-Delta COVID-19 cases
203 occurring during the study period were caused by the Alpha (UK B.1.1.7) VOC.

204 Consistent with extensive infections caused by Delta variants in Southeast Asia
205 and elsewhere ([https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-](https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html)
206 [surveillance/variant-info.html](https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html), last accessed: August 18, 2021;
207 <https://www.gov.uk/government/collections/new-sars-cov-2-variant>, last accessed:
208 August 18, 2021)¹, several patients had very recent travel histories to countries with a
209 high prevalence of these VOCs, suggesting acquisition abroad and importation into
210 Houston. Fifty-five patients with Delta Plus (Delta plus the K417N spike amino acid
211 substitution) were identified.

212 To understand the geospatial distribution of Delta in metropolitan Houston, we
213 acquired patient metadata from the electronic medical record by standard informatics
214 methods, and home address zip codes were used to visualize virus spread (**Figure 2**).
215 Delta VOCs were widely distributed throughout metropolitan Houston, with 298 distinct

216 zip codes represented (**Figure 2**), indicative of the ability of Delta variants to spread
217 very effectively and rapidly between individuals. Analysis of Delta VOCs dissemination
218 over time illustrated the rapid spread of these variants throughout the Houston
219 metroplex (**Figure 2**).

220

221 Delta Family Subvariants

222

223 A total of 893 subvariants was identified based on amino acid changes in spike protein.
224 The six most common identified in our study are shown (**Figure 3**) and these
225 represented 74% of the 8,297 Delta samples. We believe the unexpectedly high number
226 of subvariants may reflect several contributing factors, including the large population
227 sizes and genetic diversity of Delta globally, and multiple independent introductions into
228 the Houston area. Other potential contributors include high virus load in patients on
229 initial diagnosis (**Table 1**), infection of partially immunized hosts, and prolonged
230 infections occurring in relatively immunocompromised individuals⁹⁻¹². In this regard,
231 some of our patients had a history of cancer and organ transplants (**data not shown**).
232 Patients infected with the same subvariant usually lived in different zip codes and
233 generally had no apparent epidemiological link, consistent with the ability of Delta to
234 spread very rapidly. In some cases there were clear epidemiologic links between
235 patients infected with the same subvariant, including being members of the same
236 household.

237 There is a considerable lack of detailed information about patients in the United
238 States with COVID-19 caused by Delta VOCs
239 ([https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---
240 13-july-2021](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---13-july-2021), last accessed August 18, 2021). Compared to all other patients in the time
241 frame studied, there was no significant difference in gender or median age (**Table 1**).
242 However, Delta variant patients were admitted significantly less frequently than other
243 patients and had a significantly longer median hospital length of stay, but there was no
244 significant difference in mortality rate (**Table 1**). Delta cases were more likely to be
245 Asian (consistent with multiple recent entry points from abroad) and Caucasian and less
246 likely to be Hispanic or Latino, have significantly lower PCR cycle threshold (Ct) values
247 (a proxy for higher virus load, a finding consistent with increased transmissibility of Delta
248 variants) on initial diagnosis, and cause a significantly higher rate of vaccine
249 breakthrough cases (23.4% compared to 6.2% for all other variants combined) (**Table**
250 **1**). Consistent with Delta causing an increased number of vaccine breakthrough cases,
251 it has been reported that this variant has reduced sensitivity to antibody neutralization *in*
252 *vitro*¹³.

253

254 Comparison of Delta and Alpha COVID-19 Cases

255

256 The occurrence of a prominent third wave of COVID-19 cases in Houston caused by the
257 Alpha VOC (**Figure 1**) provided the opportunity of compare and contrast large disease
258 waves caused by two genetically distinct SARS-CoV-2 genotypes. For this analysis we

259 included Alpha VOC cases beginning January 1, 2021, because that time was soon
260 after our first recorded Houston Methodist case caused by this variant. The number of
261 Delta cases studied ($n = 8,297$) was much greater than the number of Alpha cases ($n =$
262 $3,262$) (**Table 2**). The two patient populations differed significantly in many
263 characteristics, including median age, ethnicity, median PCR Ct level, admission rates,
264 maximum respiratory support, rate of vaccine breakthrough, median length of stay, and
265 mortality (**Table 2**).

266

267 Vaccine Breakthrough Cases

268

269 We next analyzed vaccine breakthrough cases (**Table 3**). We found 2,187 of the 12,221
270 total patients (17.9%) for whom we have genome sequence data met the CDC definition
271 of vaccine breakthrough cases (**Table 1 and Table 3**). There was no simple relationship
272 between the time elapsed since administration of the second (booster) vaccination and
273 the date of vaccination breakthrough (data not shown). These 2,187 patients received
274 either the Pfizer-BioNTech BNT162b2 ($n = 1,875$, 86%), Moderna mRNA-1273 ($n =$
275 232 , 11%), or J&J/Janssen JNJ-78436735 ($n = 74$, 3%) vaccine; vaccine type was not
276 specified for six individuals. This distribution generally reflects the great majority of
277 BNT162b2 vaccination doses given in our health system and should not be interpreted
278 to mean that the Pfizer-BioNTech and Moderna products are unusually prone to
279 breakthrough cases, as these mRNA vaccines are highly efficacious^{6, 14-20}. Vaccinated
280 patients infected with non-Delta variants had a significantly higher Ct value on initial

281 diagnosis, likely indicating better vaccine protection, lower virus load, and decreased
282 probability of transmission. Compared to all other variants combined, a significantly
283 lower percentage (25.7% compared to 36.8%; $P<0.0004$) of patients with breakthrough
284 cases caused by Delta variants was admitted to the hospital (**Table 1 and Table 3**).

285

286 Lambda and Mu Variants of Interest

287

288 The Lambda variant of interest was first reported in November, 2020. It has very
289 recently attracted widespread media and public interest because it has caused large
290 numbers of infections in Peru and Ecuador, and has been reported to cause COVID-19
291 in the U.S^{21, 22} (<https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/>, last
292 accessed September 2, 2021). There has been speculation that Lambda may become
293 numerically prominent in the United States and other countries, in part because its spike
294 protein differs immunologically and has been reported to be partially resistant *in vitro* to
295 vaccine-induced sera and therapeutic monoclonal antibodies²³⁻²⁵. Because of this
296 concern, we inspected our large genome sequence database to determine if Lambda
297 was present, and if so, had it increased substantially in the Houston metropolitan region.
298 The analysis identified only eight cases caused by this variant of interest, the first one
299 identified in our Houston Methodist patient population in mid-July, 2021 (**Figure 4A**).
300 These patients lived in several non-contiguous zip codes throughout the metroplex, that
301 is, were not restricted to a single geographic area of greater Houston (**Figure 4A, B**).

302 The Mu VOI was initially identified in Colombia in January, 2021, and has been
303 reported to now account for 39% of cases in that country²⁶. Mu also has been found in
304 many other countries worldwide, and recently it was reported that the Mu variant has
305 increased resistance *in vitro* to antibodies elicited by vaccination with BNT162b2 and
306 natural infection by SARS-CoV-2²⁷. We identified 52 cases of COVID-19 caused by the
307 Mu VOI, and similar to the Lambda these cases were distributed in multiple areas in the
308 Houston metropolitan region (**Figure 4C, D**).

309

310

311 **Discussion**

312

313 In this work, we analyzed SARS-CoV-2 Delta VOCs population genomics and patient
314 characteristics for 12,221 patients, focusing on mid-March, 2021 through late August,
315 2021, a time frame in which there was essentially total replacement of the previously
316 dominant Alpha (B.1.1.7) VOC by Delta family VOCs. During this five-month period, a
317 substantial increase in COVID-19 cases occurred in our healthcare system and
318 throughout all of the Houston metropolitan area, virtually all driven by rapid
319 dissemination of the highly contagious Delta family variants. The study was based
320 predominantly on genome sequence analysis of 12,221 SARS-CoV-2 samples from
321 socioeconomically, geographically, and ethnically diverse patients. Several key findings
322 were made, including (i) Delta family VOCs supplanted the Alpha VOC in a relatively

323 short period of time, (ii) regardless of vaccination status, on initial diagnosis, compared
324 to patients infected by other VOCs, patients infected by Delta VOCs had significantly
325 lower Ct values, likely indicating significantly higher viral load in the nasopharynx, (iii)
326 Delta caused significantly more vaccine breakthrough cases than other VOCs, (iv)
327 significantly fewer fully vaccinated individuals required hospitalization, (v) the Lambda
328 and Mu VOIs were identified but were rare, and they did not increase to substantial
329 levels in the time frame studied.

330 Our genome sequence data document a rapid increase of Delta variant cases in
331 metropolitan Houston and a considerable corresponding decrease of COVID-19 cases
332 caused by Alpha and other variants, findings similar to epidemiologic trends observed in
333 the UK ([https://www.who.int/publications/m/item/weekly-epidemiological-update-on-](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---13-july-2021)
334 [covid-19---13-july-2021](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---13-july-2021), last accessed August 18, 2021;
335 [https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditions](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurveypilot/9july2021)
336 [anddiseases/bulletins/coronaviruscovid19infectionsurveypilot/9july2021](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurveypilot/9july2021), last accessed
337 August 18, 2021). In less than four months, Delta VOCs increased from an initial
338 documented case in our large patient population to cause 99.7% of all cases in our
339 healthcare system. The rapid increase in Delta cases we documented is responsible for
340 a prominent fourth wave of COVID-19 disease in Houston that is ongoing (**Figure 1**).
341 Our findings are consistent with Delta VOCs epidemiologic data reported from other
342 regions of the US.

343 We found that Delta was significantly more likely to cause vaccine breakthrough
344 cases (**Table 1 and Table 3**). However, importantly, 17.9% of all of our 12,221 COVID-

345 19 cases with genome sequence data occurred in fully vaccinated individuals, but only
346 589 (4.8%) of these patients required hospitalization. Vaccine breakthrough cases have
347 emerged as an area of great interest, especially so with the increasing percentage of
348 COVID-19 cases caused by Delta variants and the recognition that they are important
349 causes of breakthroughs²⁸⁻³³. Although our analysis did not identify a simple relationship
350 between the time elapsed since administration of the second booster vaccination and
351 the date of vaccination breakthrough, this is an important area for continued study.
352 Similarly, we did not study the potential relationship between vaccination breakthrough
353 and waning immunity, but studies of this topic are ongoing.

354 Some investigators have speculated that the Lambda and Mu variants may
355 become a major concern in future surges. Although in principle this is possible, our data
356 show that neither variant has increased substantially in our metropolitan area during the
357 time frame studied. Thus, our genome analysis of a large set of samples from the first
358 eight months of 2021 does not currently support this speculation, although
359 circumstances may change in the future. Because we are sequencing the genome of
360 the great majority of SARS-CoV-2 causing COVID-19 in our diverse patient population,
361 we are continuously monitoring the growth trajectory of these and other variants in a
362 major metropolitan region in the US. Thus, our ongoing near-real-time sequencing of
363 SARS-CoV-2 genomes responsible for COVID-19 cases in metropolitan Houston
364 provides a facile strategy to assess changes in the virus population composition and
365 molecular evolution in this populous area.

366 In the aggregate, our data add critical new information to the finding that these
367 three vaccines are highly efficacious in decreasing severe COVID-19 disease,
368 hospitalizations, and deaths^{6, 17, 20}. Further, the present study highlights the importance
369 of analyzing SARS-CoV-2 genome data integrated with linked patient metadata and
370 stresses the need to continue to do this in near-real time as the pandemic continues,
371 the virus evolves, and new variants with potentially increased fitness are generated.
372 Analyses of this type are also important in the context of vaccine formulation and long
373 COVID, an increasing health and economic problem globally.

374

375

376 **Acknowledgments**

377

378 We thank Drs. Marc Boom and Dirk Sostman for their ongoing support and Dr. Sasha
379 Pejerrey for editorial contributions and Dr. Heather McConnell for help with figures. The
380 research was supported by the Houston Methodist Academic Institute Infectious
381 Diseases Fund and many generous Houston philanthropists. James J. Davis was
382 funded in whole or in part with Federal funds from the National Institute of Allergy and
383 Infectious Diseases, National Institutes of Health, Department of Health and Human
384 Services, under Contract No. 75N93019C00076. The funders had no role in the design
385 and conduct of the study; collection, management, analysis, and interpretation of the
386 data; preparation, review, or approval of the manuscript; and decision to submit the
387 manuscript for publication.

388 The findings and conclusions in this article are those of the authors and do not
389 necessarily reflect the views of the U.S. Army.

390 We declare that we have no conflict of interest.

391

392

393 **Author Contributions**

394

395 P.A.C., R.J.O., S.W.L., S.S., and J.M.M. had full access to all study data and take
396 responsibility for the integrity of the data and the accuracy of the data analysis; concept
397 and design by J.M.M., P.A.C., R.J.O., and S.W.L; data acquisition, analysis, or
398 interpretation by all authors; drafting of the manuscript by all authors; statistical analysis
399 by P.A.C.; funding obtained by J.M.M. and J.J.D.; overall supervision by J.M.M; P.A.C.,
400 R.J.O., and S.W.L. contributed equally and are co-first authors.

401

402

403 **Institutional Review Board statement:** This work was approved by the Houston
404 Methodist Research institutional review board (IRB1010-0199).

405

406

407 **Additional Information:** Genome data used in this study have been deposited to
408 GISAID.

409

410 **Figure Legends**

411

412 **Figure 1** Epidemiologic curve showing four COVID-19 disease waves in Houston
413 Methodist patients. Number of new COVID-19 cases (y-axis) totals are shown as a +/-
414 three-day moving average. Each of the four waves is shown in a different color simply
415 as a stylistic device. The first and second waves were composed of a heterogenous
416 array of SARS-CoV-2 genotypes. The Alpha variant shown in the third wave and the
417 Delta variant shown in the fourth indicate their numeric prominence in those waves, and
418 should not be interpreted to mean that all cases in the third and fourth waves were
419 caused by Alpha and Delta VOCs, respectively. The figure was generated with Tableau
420 version 2020.3.4 (Tableau Software, LLC, Seattle, WA). The curve mirrors that of
421 disease activity in metropolitan Houston, Texas.

422

423 **Figure 2** Increase in Delta frequency over time and distribution in metropolitan
424 Houston. The study time frame was March 15, 2021 through August 26, 2021. **A:**
425 Cumulative increase in Delta during the study period; y-axis is the cumulative number of
426 new COVID-19 cases. At the end of the study period, Delta caused 99.7% of all COVID-
427 19 cases. **B – E:** Geospatial distribution of Delta based on home address zip code for
428 each patient. **B:** April 15 – May 15; **C:** April 15 – June 15; **D:** April 15 – July 15; **E:** April
429 15 – August 26. Figures were generated using Tableau version 2020.3.4. (Tableau
430 Software, LLC, Seattle, WA).

431

432 **Figure 3** Structural changes present in spike protein of the six most abundant Delta
433 subvariants identified in the study. The numbers denote the number of patients with
434 each subvariant identified in this study. These six subvariants represented 74% of the
435 8,297 Delta samples in our study. S1-NTD, S1 domain-aminoterminal domain; S1-RBD,
436 S1 domain-receptor binding domain; S1, S1 domain; S2, S2 domain. The figure is a
437 modified version of one published previously⁸.

438

439 **Figure 4** Lambda and Mu variants identified in metropolitan Houston in our patient
440 population. **A:** cumulative increase in the cases caused by Lambda variants identified in
441 the study; **B:** geospatial distribution of these Lambda variants based on the home
442 address zip code for each patient. **C:** cumulative increase in cases caused by the Mu
443 variants identified in the study; **D:** geospatial distribution of the Mu variants based on
444 the home address zip code for each patient. Figures were generated using Tableau
445 version 2020.3.4. (Tableau Software, LLC, Seattle, WA).

446

447

448 **References**

449

- 450 [1] Dhar MS, Marwal R, Radhakrishnan V, Ponnusamy K, Jolly B, Bhojar RC, Fatihi S, Datta M,
451 Singh P, Sharma U, Ujjainia R, Naushin S, Bhateja N, Divakar MK, Sardana V, Singh MK, Imran M,
452 Senthivel V, Maurya R, Jha N, Mehta P, Rophina M, Arvinden V, Chaudhary U, Thukral L, Pandey
453 R, Dash D, Faruq M, Lall H, Gogia H, Madan P, Kulkarni S, Chauhan H, Sengupta S, Kabra S,
454 Consortium TIS-C-G, Singh SK, Agrawal A, Rakshit P: Genomic characterization and
455 Epidemiology of an emerging SARS-CoV-2 variant in Delhi, India. medRxiv
456 2021:2021.06.02.21258076.
- 457 [2] Hacisuleyman E, Hale C, Saito Y, Blachere NE, Bergh M, Conlon EG, Schaefer-Babajew DJ,
458 DaSilva J, Muecksch F, Gaebler C, Lifton R, Nussenzweig MC, Hatzioannou T, Bieniasz PD,
459 Darnell RB: Vaccine Breakthrough Infections with SARS-CoV-2 Variants. N Engl J Med 2021,
460 384:2212-8.
- 461 [3] Brosh-Nissimov T, Orenbuch-Harroch E, Chowers M, Elbaz M, Nesher L, Stein M, Maor Y,
462 Cohen R, Hussein K, Weinberger M, Zimhony O, Chazan B, Najjar R, Zayyad H, Rahav G, Wiener-
463 Well Y: BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully-vaccinated
464 hospitalized COVID-19 patients in Israel. Clin Microbiol Infect 2021.
- 465 [4] COVID-19 Vaccine Breakthrough Infections Reported to CDC - United States, January 1-April
466 30, 2021. MMWR Morb Mortal Wkly Rep 2021, 70:792-3.
- 467 [5] Kustin T, Harel N, Finkel U, Perchik S, Harari S, Tahor M, Caspi I, Levy R, Leshchinsky M, Ken
468 Dror S, Bergerzon G, Gadban H, Gadban F, Eliassian E, Shimron O, Saleh L, Ben-Zvi H, Keren
469 Taraday E, Amichay D, Ben-Dor A, Sagas D, Strauss M, Shemer Avni Y, Huppert A, Kepten E,
470 Balicer RD, Netzer D, Ben-Shachar S, Stern A: Evidence for increased breakthrough rates of
471 SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. Nat Med 2021.
- 472 [6] Tenforde MW, Patel MM, Ginde AA, Douin DJ, Talbot HK, Casey JD, Mohr NM, Zepeski A,
473 Gaglani M, McNeal T, Ghamande S, Shapiro NI, Gibbs KW, Files DC, Hager DN, Shehu A, Prekker
474 ME, Erickson HL, Exline MC, Gong MN, Mohamed A, Henning DJ, Peltan ID, Brown SM, Martin
475 ET, Monto AS, Khan A, Hough CT, Busse L, Ten Lohuis CC, Duggal A, Wilson JG, Gordon AJ, Qadir
476 N, Chang SY, Mallow C, Gershengorn HB, Babcock HM, Kwon JH, Halasa N, Chappell JD, Lauring
477 AS, Grijalva CG, Rice TW, Jones ID, Stubblefield WB, Baughman A, Womack KN, Lindsell CJ, Hart
478 KW, Zhu Y, Olson SM, Stephenson M, Schrag SJ, Kobayashi M, Verani JR, Self WH: Effectiveness
479 of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United States.
480 Clin Infect Dis 2021.
- 481 [7] Long SW, Olsen RJ, Christensen PA, Subedi S, Olson R, Davis JJ, Saavedra MO, Yerramilli P,
482 Pruitt L, Reppond K, Shyer MN, Cambric J, Finkelstein IJ, Gollihar J, Musser JM: Sequence
483 Analysis of 20,453 Severe Acute Respiratory Syndrome Coronavirus 2 Genomes from the
484 Houston Metropolitan Area Identifies the Emergence and Widespread Distribution of Multiple
485 Isolates of All Major Variants of Concern. Am J Pathol 2021, 191:983-92.
- 486 [8] Olsen RJ, Christensen PA, Long SW, Subedi S, Hodjat P, Olson R, Nguyen M, Davis JJ,
487 Yerramilli P, Saavedra MO, Pruitt L, Reppond K, Shyer MN, Cambric J, Gadd R, Thakur RM,
488 Batajoo A, Finkelstein IJ, Gollihar J, Musser JM: Trajectory of Growth of Severe Acute

489 Respiratory (SARS-CoV-2) Syndrome Coronavirus 2 Variants in Houston, Texas, January through
490 May 2021, Based on 12,476 Genome Sequences. *Am J Pathol* 2021.

491 [9] Clark SA, Clark LE, Pan J, Coscia A, McKay LGA, Shankar S, Johnson RI, Brusica V, Choudhary
492 MC, Regan J, Li JZ, Griffiths A, Abraham J: SARS-CoV-2 evolution in an immunocompromised
493 host reveals shared neutralization escape mechanisms. *Cell* 2021, 184:2605-17.e18.

494 [10] Choi B, Choudhary MC, Regan J, Sparks JA, Padera RF, Qiu X, Solomon IH, Kuo HH, Boucau J,
495 Bowman K, Adhikari UD, Winkler ML, Mueller AA, Hsu TY, Desjardins M, Baden LR, Chan BT,
496 Walker BD, Lichterfeld M, Brigl M, Kwon DS, Kanjilal S, Richardson ET, Jonsson AH, Alter G,
497 Barczak AK, Hanage WP, Yu XG, Gaiha GD, Seaman MS, Cernadas M, Li JZ: Persistence and
498 Evolution of SARS-CoV-2 in an Immunocompromised Host. *N Engl J Med* 2020, 383:2291-3.

499 [11] Baang JH, Smith C, Mirabelli C, Valesano AL, Manthei DM, Bachman MA, Wobus CE, Adams
500 M, Washer L, Martin ET, Luring AS: Prolonged Severe Acute Respiratory Syndrome Coronavirus
501 2 Replication in an Immunocompromised Patient. *J Infect Dis* 2021, 223:23-7.

502 [12] Hensley MK, Bain WG, Jacobs J, Nambulli S, Parikh U, Cillo A, Staines B, Heaps A,
503 Sobolewski MD, Rennick LJ, Macatangay BJC, Klammar-Blain C, Kitsios GD, Methé B,
504 Somasundaram A, Bruno TC, Cardello C, Shan F, Workman C, Ray P, Ray A, Lee J, Sethi R,
505 Schwarzmann WE, Ladinsky MS, Bjorkman PJ, Vignali DA, Duprex WP, Agha ME, Mellors JW,
506 McCormick KD, Morris A, Haidar G: Intractable Coronavirus Disease 2019 (COVID-19) and
507 Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication in a
508 Chimeric Antigen Receptor-Modified T-Cell Therapy Recipient: A Case Study. *Clinical Infectious*
509 *Diseases* 2021.

510 [13] Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, Planchais C,
511 Porrot F, Robillard N, Puech J, Prot M, Gallais F, Gantner P, Velay A, Le Guen J, Kassis-Chikhani
512 N, Edriss D, Belec L, Seve A, Courtellemont L, Péré H, Hocqueloux L, Fafi-Kremer S, Prazuck T,
513 Mouquet H, Bruel T, Simon-Lorière E, Rey FA, Schwartz O: Reduced sensitivity of SARS-CoV-2
514 variant Delta to antibody neutralization. *Nature* 2021.

515 [14] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G,
516 Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper
517 D, Frenck RW, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S,
518 Dormitzer PR, Şahin U, Jansen KU, Gruber WC: Safety and Efficacy of the BNT162b2 mRNA
519 Covid-19 Vaccine. *New England Journal of Medicine* 2020, 383:2603-15.

520 [15] Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA,
521 Roupheal N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H,
522 Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L,
523 Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S,
524 Ivarsson M, Miller J, Zaks T: Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *New*
525 *England Journal of Medicine* 2020, 384:403-16.

526 [16] Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL,
527 Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Collins AM, Colin-Jones R, Cutland CL, Darton
528 TC, Dheda K, Duncan CJA, Emary KRW, Ewer KJ, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A,
529 Goodman AL, Green CM, Green CA, Heath PT, Hill C, Hill H, Hirsch I, Hodgson SHC, Izu A, Jackson
530 S, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Lawrie AM, Lelliott A, Libri V, Lillie
531 PJ, Mallory R, Mendes AVA, Milan EP, Minassian AM, McGregor A, Morrison H, Mujadidi YF,
532 Nana A, O'Reilly PJ, Padayachee SD, Pittella A, Plested E, Pollock KM, Ramasamy MN, Rhead S,

533 Schwarzbold AV, Singh N, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Tarrant R,
534 Thomson EC, Török ME, Toshner M, Turner DPJ, Vekemans J, Villafana TL, Watson MEE,
535 Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ: Safety and efficacy of the
536 ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four
537 randomised controlled trials in Brazil, South Africa, and the UK. *Lancet* 2021, 397:99-111.
538 [17] Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, Stowe J, Tessier E,
539 Groves N, Dabrera G, Myers R, Campbell CNJ, Amirthalingam G, Edmunds M, Zambon M, Brown
540 KE, Hopkins S, Chand M, Ramsay M: Effectiveness of Covid-19 Vaccines against the B.1.617.2
541 (Delta) Variant. *New England Journal of Medicine* 2021.
542 [18] Abu-Raddad LJ, Chemaitelly H, Butt AA: Effectiveness of the BNT162b2 Covid-19 Vaccine
543 against the B.1.1.7 and B.1.351 Variants. *New England Journal of Medicine* 2021, 385:187-9.
544 [19] Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, Hernán MA, Lipsitch M, Reis B,
545 Balicer RD: BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. *New*
546 *England Journal of Medicine* 2021, 384:1412-23.
547 [20] Jagadeesh Kumar V, Sowpati DT, Munigela A, Banu S, Siva AB, Sasikala M, Nutalapati C,
548 Kulkarni A, Mukherjee P, Zaveri L, Team CC-, Team AHC-Vs, Tallapaka KB, Reddy DN: Clinical
549 outcomes in vaccinated individuals hospitalized with Delta variant of SARS-CoV-2. *medRxiv*
550 2021:2021.07.13.21260417.
551 [21] Padilla-Rojas C, Jimenez-Vasquez V, Hurtado V, Mestanza O, Molina IS, Barcena L, Morales
552 Ruiz S, Acedo S, Lizarraga W, Bailon H, Cáceres O, Galarza M, Rojas-Serrano N, Vargas-Herrera
553 N, Lope-Pari P, Huayra J, Solari L: Genomic analysis reveals a rapid spread and predominance of
554 lambda (C.37) SARS-COV-2 lineage in Peru despite circulation of variants of concern. *J Med Virol*
555 2021.
556 [22] Romero PE, Dávila-Barclay A, Salvatierra G, González L, Cuicapuza D, Solis L, Marcos-
557 Carbajal P, Huancachoque J, Maturrano L, Tsukayama P: The Emergence of SARS-CoV-2 Variant
558 Lambda (C.37) in South America. *medRxiv* 2021:2021.06.26.21259487.
559 [23] Tada T, Zhou H, Dcosta BM, Samanovic MI, Mulligan MJ, Landau NR: The Spike Proteins of
560 SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India Provide Partial Resistance to
561 Vaccine-elicited and Therapeutic Monoclonal Antibodies. *bioRxiv* 2021:2021.05.14.444076.
562 [24] Kimura I, Kosugi Y, Wu J, Yamasoba D, Butlertanaka EP, Tanaka YL, Liu Y, Shirakawa K,
563 Kazuma Y, Nomura R, Horisawa Y, Tokunaga K, Takaori-Kondo A, Arase H, Consortium TGtPJ,
564 Saito A, Nakagawa S, Sato K: SARS-CoV-2 Lambda variant exhibits higher infectivity and immune
565 resistance. *bioRxiv* 2021:2021.07.28.454085.
566 [25] Liu H, Wei P, Zhang Q, Aviszus K, Linderberger J, Yang J, Liu J, Chen Z, Waheed H, Reynoso
567 L, Downey GP, Frankel SK, Kappler J, Marrack P, Zhang G: The Lambda variant of SARS-CoV-2
568 has a better chance than the Delta variant to escape vaccines. *bioRxiv* 2021:2021.08.25.457692.
569 [26] Laiton-Donato K, Franco-Muñoz C, Álvarez-Díaz DA, Ruiz-Moreno HA, Usme-Ciro JA, Andrés
570 Prada D, Reales-González J, Corchuelo S, Herrera-Sepúlveda MT, Naizaque J, Santamaría G,
571 Rivera J, Rojas P, Hernández Ortiz J, Cardona A, Malo D, Prieto-Alvarado F, Gómez FR, Wiesner
572 M, Ospina Martínez ML, Mercado-Reyes M: Characterization of the emerging B.1.621 variant of
573 interest of SARS-CoV-2. *medRxiv* 2021:2021.05.08.21256619.
574 [27] Uriu K, Kimura I, Shirakawa K, Takaori-Kondo A, Nakada T-a, Kaneda A, Consortium TGtPJ,
575 Nakagawa S, Sato K: Ineffective neutralization of the SARS-CoV-2 Mu variant by convalescent
576 and vaccine sera. *bioRxiv* 2021:2021.09.06.459005.

- 577 [28] Brown CM, Vostok J, Johnson H, Burns M, Gharpure R, Sami S, Sabo RT, Hall N, Foreman A,
578 Schubert PL, Gallagher GR, Fink T, Madoff LC, Gabriel SB, MacInnis B, Park DJ, Siddle KJ, Harik V,
579 Arvidson D, Brock-Fisher T, Dunn M, Kearns A, Laney AS: Outbreak of SARS-CoV-2 Infections,
580 Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings -
581 Barnstable County, Massachusetts, July 2021. *MMWR Morb Mortal Wkly Rep* 2021, 70:1059-62.
- 582 [29] Chia PY, Xiang Ong SW, Chiew CJ, Ang LW, Chavatte J-M, Mak T-M, Cui L, Kalimuddin S,
583 Chia WN, Tan CW, Ann Chai LY, Tan SY, Zheng S, Pin Lin RT, Wang L, Leo Y-S, Lee VJ, Lye DC,
584 Young BE: Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough
585 infections: a multi-center cohort study. *medRxiv* 2021:2021.07.28.21261295.
- 586 [30] Sheikh A, McMenemy J, Taylor B, Robertson C: SARS-CoV-2 Delta VOC in Scotland:
587 demographics, risk of hospital admission, and vaccine effectiveness. *Lancet* 2021, 397:2461-2.
- 588 [31] Riemersma KK, Grogan BE, Kita-Yarbro A, Halfmann PJ, Segaloff HE, Kocharian A, Florek KR,
589 Westergaard R, Bateman A, Jeppson GE, Kawaoka Y, O'Connor DH, Friedrich TC, Grande KM:
590 Shedding of Infectious SARS-CoV-2 Despite Vaccination. *medRxiv* 2021:2021.07.31.21261387.
- 591 [32] Bergwerk M, Gonen T, Lustig Y, Amit S, Lipsitch M, Cohen C, Mandelboim M, Gal Levin E,
592 Rubin C, Indenbaum V, Tal I, Zavitan M, Zuckerman N, Bar-Chaim A, Kreiss Y, Regev-Yochay G:
593 Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. *New England Journal of*
594 *Medicine* 2021.
- 595 [33] Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman L, Haas EJ, Milo R, Alroy-
596 Preis S, Ash N, Huppert A: Waning immunity of the BNT162b2 vaccine: A nationwide study from
597 Israel. *medRxiv* 2021:2021.08.24.21262423.

598

599

600 **Table 1. Summary of pertinent patient metadata for the 12,221 unique patients**

	Delta Variant	Other Variants	Total	Statistical Analysis
No. (%) with data	8297 (67.9%)	3924 (32.1%)	12221	
Patient Characteristics				
Median Age (Years)	47.3	47.9	47.5	$P=0.1980$ Mann-Whitney
Female	4390 (52.9%)	2033 (51.8%)	6423 (52.6%)	$P=0.2605$ Fisher's exact test
Male	3907 (47.1%)	1891 (48.2%)	5798 (47.4%)	
Ethnicity				
Caucasian	3648 (44.1%)	1532 (39.3%)	5180 (42.6%)	$P<0.0001$ Chi-square
Hispanic or Latino	2092 (25.3%)	1199 (30.8%)	3291 (27.1%)	
Black	1877 (22.7%)	913 (23.4%)	2790 (22.9%)	
Asian	311 (3.8%)	114 (2.9%)	425 (3.5%)	
Native American	14 (0.2%)	15 (0.4%)	29 (0.2%)	
Hawaiian/Pacific Islander	20 (0.2%)	5 (0.1%)	25 (0.2%)	
Unavailable	303 (3.7%)	119 (3.1%)	422 (3.5%)	
BMI				
Median BMI	29.7	30.3	30.0	$P<0.0001$ Mann-Whitney
Admission Data				
Admitted	3321 (40.0%)	2120 (54.0%)	5441 (44.5%)	$P<0.0001$ Fisher's exact test Odds Ratio: 0.554 (95% CI 0.511- 0.600)
Not Admitted	4976 (60.0%)	1804 (46.0%)	6780 (55.5%)	
Median LOS (Days)	5.8	5.0	5.3	$P<0.0001$ Mann-Whitney
Max Respiratory Support				
ECMO	11 (0.3%)	7 (0.3%)	18 (0.3%)	$P<0.0001$

Mechanical Ventilation	346 (10.4%)	167 (7.9%)	513 (9.4%)	Chi-square
Non-Invasive Ventilation	346 (10.4%)	188 (8.9%)	534 (9.8%)	
High Flow Oxygen	946 (28.5%)	403 (19.0%)	1349 (24.8%)	
Low Flow Oxygen	1113 (33.5%)	876 (41.3%)	1989 (36.6%)	
Room Air	559 (16.8%)	479 (22.6%)	1038 (19.1%)	
Mortality				
Alive	7985 (96.2%)	3760 (95.8%)	11745 (96.1%)	$P=0.2707$
Deceased	312 (3.8%)	164 (4.2%)	476 (3.9%)	Fisher's exact test
				Odds Ratio: 0.896 (95% CI 0.739- 1.087)
Median PCR Cycle Threshold				
Abbott Alinity	20.71 n=2659	25.57 n=1411	n=4070	$P<0.0001$ Mann-Whitney
Hologic Panther	21.30 n=(808)	26.05 n=(474)	n=1282	$P<0.0001$ Mann-Whitney
Vaccine				
No vaccine	6191 (74.6%)	3526 (89.9%)	9717 (79.5%)	Chi-square
>7 days past 1st vaccine	161 (1.9%)	156 (4.0%)	317 (2.6%)	
>14 days past 2nd vaccine	1945 (23.4%)	242 (6.2%)	2187 (17.9%)	

601 Data include 12,221 unique patients with high-quality sequence results between March 15, 2021 and August 26,
 602 2021. BMI: body mass index; CI: confidence interval; ECMO: extracorporeal membrane oxygenation; LOS: length of
 603 stay

604

605

606 **Table 2. Comparison of pertinent patient metadata for 9,693 unique Delta VOC**
 607 **and Alpha VOC patients**

	Delta Variant	Alpha Variant	Total	Statistical Analysis
No. (%) with data	8297 (71.8%)	3262 (28.2%)	11559	
Patient Characteristics				
Median Age (Years)	47.3	49.4	48.0	$P < 0.0001$ Mann-Whitney
Female	4390 (52.9%)	1708 (52.4%)	6098 (52.8%)	$P = 0.6049$ Fisher's exact test
Male	3907 (47.1%)	1554 (47.6%)	5461 (47.2%)	
Ethnicity				
Caucasian	3648 (44.1%)	1279 (39.4%)	4927 (42.8%)	$P < 0.0001$ Chi-square
Hispanic or Latino	2092 (25.3%)	967 (29.8%)	3059 (26.6%)	
Black	1877 (22.7%)	760 (23.4%)	2637 (22.9%)	
Asian	311 (3.8%)	127 (3.9%)	438 (3.8%)	
Native American	14 (0.2%)	12 (0.4%)	26 (0.2%)	
Hawaiian/Pacific Islander	20 (0.2%)	3 (0.1%)	23 (0.2%)	
Unavailable	303 (3.7%)	96 (3.0%)	399 (3.5%)	
BMI				
Median BMI	29.7	30.5	30.0	$P < 0.0001$ Mann-Whitney
Admission Data				
Admitted	3321 (40.0%)	1737 (53.2%)	5058 (43.8%)	$P < 0.0001$ Fisher's exact test
Not Admitted	4976 (60.0%)	1525 (46.8%)	6501 (56.2%)	
				Odds Ratio: 0.586 (95% CI 0.540- 0.636)
Median LOS (Days)	5.8	5.1	5.3	$P = 0.0004$ Mann-Whitney
Max Respiratory Support				

ECMO	11 (0.3%)	7 (0.4%)	18 (0.4%)	$P<0.0001$
Mechanical Ventilation	346 (10.4%)	155 (8.9%)	501 (9.9%)	Chi-square
Non-Invasive Ventilation	346 (10.4%)	165 (9.5%)	511 (10.1%)	
High Flow Oxygen	946 (28.5%)	369 (21.2%)	1315 (26.0%)	
Low Flow Oxygen	1113 (33.5%)	714 (41.1%)	1827 (36.1%)	
Room Air	559 (16.8%)	327 (18.8%)	886 (17.5%)	
Mortality				
Alive	7985 (96.2%)	3099 (95.0%)	11084 (95.9%)	$P=0.0030$
Deceased	312 (3.8%)	163 (5.0%)	475 (4.1%)	Fisher's exact test
				Odds Ratio: 0.743 (95% CI 0.612- 0.902)
Median PCR Cycle Threshold				
Abbott Alinity	20.71 n=2659	22.43 n=1109	n=3768	$P<0.0001$ Mann-Whitney
Hologic Panther	21.30 n=808	24.20 n=375	n=1183	$P<0.0001$ Mann-Whitney
Vaccine				
No vaccine	6191 (74.6%)	3000 (92.0%)	9191 (79.5%)	$P<0.0001$
>7 days past 1st vaccine	161 (1.9%)	134 (4.1%)	295 (2.6%)	Chi-square
>14 days past 2nd vaccine	1945 (23.4%)	128 (3.9%)	2073 (17.9%)	

608 Data include 11,559 unique patients with high-quality sequence results between January 1, 2021 and August 26,
 609 2021. BMI: body mass index; CI: confidence interval; ECMO: extracorporeal membrane oxygenation; LOS: length of
 610 stay

611

612

613

614 **Table 3. Summary of pertinent patient metadata for the 2,187 fully vaccinated**
 615 **patients**

	Vaccinated	Not Vaccinated	Total	Statistical Analysis
Median PCR Cycle Threshold				
Abbott Alinity	20.81 n=822	22.27 n=3248	n=4070	P=0.0172 Mann-Whitney
Hologic Panther	22.40 n=277	23.30 n=1005	n=1282	P=0.2009 Mann-Whitney
Admission Data				
Admitted	589 (26.9%)	4852 (48.4%)	5441 (44.5%)	P<0.0001 Fisher's exact test Odds Ratio: 0.394 (95% CI 0.355-0.436)
Not Admitted	1598 (73.1%)	5182 (51.6%)	6780 (55.5%)	
Delta Variant				
	Delta Variant	Other Variants	Total	
No. (%) with data	1945 (88.9%)	242 (11.1%)	2187	
Admission Data				
Admitted	500 (25.7%)	89 (36.8%)	589 (26.9%)	P=0.0004 Fisher's exact test Odds Ratio: 0.595 (95% CI 0.449-0.787)
Not Admitted	1445 (74.3%)	153 (63.2%)	1598 (73.1%)	

616

617

618

619







